MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24

MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24 Share Price

DE000ME48AT1

Market Closed - Börse Stuttgart 10:25:01 28/06/2024 pm IST
0.025 ^EUR	0.00%

Current month	+19.05%
1 month	+31.58%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT

More news

Quotes 5-day view

Date	Price	Change
28/24/28	0.025	0.00%
27/24/27	0.025	-3.85%
26/24/26	0.026	+8.33%
25/24/25	0.024	0.00%
24/24/24	0.024	+14.29%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 10:25 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Morgan Stanley
WKN	ME48AT
ISIN	DE000ME48AT1
Date issued	28/11/2023
Strike	54 $
Maturity	20/09/2024 (83 Days)
Parity	10 : 1
Emission price	0.34 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.39 €
Lowest since issue	0.016 €
Delta	0.1x
Omega	11.91
Premium	30.85x
Gearing	121.17x
Moneyness	0.7691
Difference Strike	12.47 $
Difference Strike %	+23.09%
Spread	0.016 €
Spread %	40.00%
Theoretical value	0.0320
Implied Volatility	39.95 %
Total Loss Probability	93.03 %
Intrinsic value	0.000000
Present value	0.0320
Break even	54.34 €
Theta	-0.01x
Vega	0x
Rho	0x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.53 USD

Average target price

53.19 USD

Spread / Average Target

+28.09%

Consensus